AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Layoffs loom as Intel’s new CEO moves to fix slow decision-making and chip production
2
“Suffocating innovation”: Intel’s new CEO dismantles hierarchy
3
Intel’s breakup begins with sale of $8.75B-valued Altera to private equity giant Silver Lake
4
Tenable names co-CEOs to lead after Amit Yoran’s death
5
Armis president sets bold goal: $1B in sales in three years, IPO in two
More news

BioCanCell

9 stories about BioCanCell
הבורסה לניירות ערך רחוב אחוזת בית תל אביב

Anchiano Therapeutics Schedules TASE Delisting

14.03.19|Lilach Baumer
Based in Jerusalem and Cambridge, Massachusetts, clinical-stage Anchiano develops gene therapies for cancer, with a special focus on bladder cancer
נאסדק

Cancer Treatment Company Anchiano Therapeutics Wants to List on Nasdaq

09.01.19|Lilach Baumer
The company formerly known as BioCanCell submitted a prospectus to the SEC on Monday, with Oppenheimer & Co. as the sole underwriter
לן בלווטניק בעל השליטה בכת"ב

Three Portfolio Companies of Len Blavatnik's Clal Biotechnology Raise Cash in One Week

04.07.18|CTech
Clal Biotechnology Industries is an Israel-based life sciences investment company
בורסה בורסת תל אביב 5

Cancer Treatment Company BioCanCell Raises $22.9 Million in Private Placement

02.07.18|CTech
The company announced the issuance of 5.9 million new shares in April
מפעל השחר העולה שוקולד

CTech’s Monday Roundup of Israeli Tech News

23.04.18|CTech
Israeli satellite operator Spacecom bundled in a bid for Tel Aviv real estate. eBay Israel general manager Yuval Matalon steps down
תל אביב בורסה Tel Aviv Stock Exchange

Attempting to Delist, Cancer Treatment Company BioCanCell Issues New Shares

23.04.18|Dror Reich
The company diluted existing investors that opposed its plans to delist from the Tel Aviv Stock Exchange
מטבע ביטקוין דולר דולרים

CTech’s Daily Israeli Tech News Roundup

23.01.18|CTech
BioCanCell raises $25 million. Israel lags behind most developed countries on the Inclusive Development Index. Activist investor Jana Partners takes stake in Teva
default image

Pharma Company BioCanCell Raises $25 million, Plans to Go Public in the U.S.

23.01.18|Asaf Shalev
The company said it will use the funding for clinical trials of BC-819, a drug being designed to treat early stage bladder cancer
default image

Cancer Treatment Company Negotiating $20-25 Million Capital Injection

29.10.17|Lilach Baumer
The potential investors condition the investment on delisting BioCanCell from the Tel Aviv Stock Exchange